Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
Abstract Small cell lung cancer (SCLC) is an extremely aggressive cancer with a relatively low median survival rate after diagnosis. Treatment options such as chemotherapy or combination immunotherapy have shown clinical benefits, but resistance and relapse can occur. Antibody–drug conjugates (ADCs)...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-08-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-024-01171-1 |